MGTX MeiraGTx Holdings plc

-0.53  -2%
Previous Close 29.22
Open 29.25
Price To Book 6.63
Market Cap 956,598,219
Shares 33,342,566
Volume 107,706
Short Ratio
Av. Daily Volume 150,628

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated in 2019.
Phase 1/2 data released May 14, 2019 - met primary endpoint of safety and tolerability. Full data to be presented later in 2019.
Phase 1/2 data 2H 2019.
X-Linked Retinitis Pigmentosa
Phase 1/2 trial to be initiated 2H 2019.
Phase 1/2 data due 2H 2019.

Latest News

  1. Why McEwen Mining, MeiraGTx Holdings, and Electronic Arts Slumped Today
  2. 3 Small-Cap Biotech Stocks That Soared Last Week
  3. Hedge Funds Have Never Been This Bullish On MeiraGTx Holdings plc (MGTX)
  4. Estimating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)
  5. 3 Biotech Stocks That Soared Last Week: Are They Buys?
  6. Why This Biotech Stock Looks Prime For A Johnson & Johnson Buyout
  7. MeiraGTx Reports First Quarter 2019 Financial Results and Provides Corporate Update
  8. MeiraGTx Announces Positive 6-Month Data from Phase 1/2 Trial of Investigational Gene Therapy AAV-RPE65 for RPE65-Deficiency
  9. MeiraGTx Appoints Nicole Seligman to Board of Directors
  10. MeiraGTx to Present at Bank of America Merrill Lynch Healthcare Conference
  11. MeiraGTx Announces Upcoming Presentation on Achromatopsia Gene Therapy Candidate AAV-CNGA3 at ARVO 2019
  12. The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
  13. 5 Biotech Stocks Defying the Medicare-for-All Scare
  14. MeiraGTx Reports Full Year 2018 Financial Results
  15. 10 Stocks For The Gene Therapy Revolution
  16. MeiraGTx to Present at the Barclays Global Healthcare Conference
  17. Why NOW Is the Time to Buy Gene Therapy Stocks
  18. MeiraGTx Announces $80 Million Private Placement of Ordinary Shares
  19. MeiraGTx Appoints Martin Indyk, Ph.D. to Board of Directors